CT-388 Tracker
Roche’s weekly dual agonist — and your protocol today
CT-388 is a once-weekly injectable GLP-1/GIP dual receptor agonist developed by Roche (acquired through Carmot Therapeutics) — the same dual-receptor class as tirzepatide. It is investigational and not FDA approved. Shotlee is the free app to track your current protocol while it advances.
What is CT-388?
CT-388 is a once-weekly injectable GLP-1/GIP dual receptor agonist that Roche obtained through its acquisition of Carmot Therapeutics. It targets the same two receptors as tirzepatide (Mounjaro/Zepbound), combining appetite suppression with the GIP-driven metabolic effect.
CT-388 reported strong early-phase weight loss and is part of Roche’s broader obesity portfolio, which also includes the oral CT-996 and the amylin analog petrelintide. It is one of the most-watched injectable dual agonists behind the approved tirzepatide and investigational retatrutide.
CT-388 Key Facts
What to Track in Shotlee
Build clean baseline data now so you can compare if next-gen dual agonists reach the market.
Development Outlook
Protocol FAQs
CT-388 is Roche’s once-weekly injectable GLP-1/GIP dual receptor agonist (from the Carmot Therapeutics acquisition), in clinical development for obesity. It targets the same receptors as tirzepatide and is investigational, not FDA approved.
Both are GLP-1/GIP dual agonists, but CT-388 is a different molecule from Roche and is still investigational, while tirzepatide (Mounjaro/Zepbound) is FDA approved and available. No head-to-head data exists.
No. Both are Roche obesity candidates, but CT-388 is an injectable GLP-1/GIP dual agonist, while CT-996 is an oral small-molecule GLP-1 agonist.
It is investigational and only available in trials. Timing depends on later-stage results and regulatory review. Follow Shotlee’s tracker pages for updates.
Yes. Shotlee logs doses, weight, side effects, and labs for your current medication for free, so you have a clean baseline if next-gen dual agonists like CT-388 launch.
Track Your Protocol in Shotlee
Free dose logs, weight trends, and side effect tracking — ready for the next-gen dual agonists.